Key facts
- It has raised $2.2M; the latest was Seed Round ($1.7M) in Mar 2025.
- Notable investors include Plug and Play Tech Center, Exist Federal Ministry of Economics and Energy, IBG Beteiligungsgesellschaft Sachsen-Anhalt, MPF Start-up Accelerator, Max Planck Gesellschaft — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Eversyn
- ·The full record, as it builds
Funding rounds
No funding rounds for Eversyn are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eversyn
Developer of a biotechnology company intended to produce nucleotide sugars. The company is engineering biocatalysts to produce human milk oligosaccharides and tailor the glycosylation of therapeutic proteins, enabling biotechnologists to have access to provide the magnitude of orders cheaper than the current production costs.
- Sector
- Healthcare
- HQ
- Magdeburg, Germany
- Founded
- 2022
- Employees
- 8
- Website
- eversyn.de/
- Ownership
- Privately Held (backing)
Eversyn doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eversyn shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eversyn in its N-PORT filings yet. We sweep new filings monthly.